


APPROACH TO THE SYNTHESIS OF STEFFIMYCINS
 PREPARATION AND ANTIBACTERIAL ACTIVITY OF (±) 8-DEMETHOXY 7-EPI (?) STEFFIMYCINONE


J.P. Gesson, J.C. Jacquesy and B. Renoux
 Laboratoire de CHIMIE XII - E.R.A. N° 556
 40, Avenue du Recteur Pineau - 86022 Poitiers (France)

Abstract : Title compound has been prepared in five steps from the readily available 3-chloro 5-hydroxy 7-methoxy 1,4-naphthoquinone, and tested for antibacterial activity.

Steffimycin A 1 first isolated in 1967 from culture of *Streptomyces steffisburgensis* exhibits antibiotic activity against gram-positive bacteria but also in vitro cytotoxic properties (KB, HERPES)¹. Structure of 1 was proposed on the basis of spectroscopic data and chemical degradation, however stereochemistry and absolute configuration of ring A functions were not determined². Interesting features of the corresponding aglycone, steffimycinone 2, are the presence of a C₁₀ carbonyl and a C₈ methoxy groups together with more common functions of ring A anthracyclines : a C₉ methyl group with a C₇-C₉ diol. Moreover this 11-deoxyanthracyclinone is characterized by a relatively rare methoxy group at C₂³.



- 1 R₁=OMe, R₂=H
3 R₁=OMe, R₂=Me
4 R₁=R₂=H




- 2 R₁=OMe, R₂=OH
5 R₁=R₂=H

Other closely related and biologically active compounds are steffimycin B⁴ 3 (4'-O methyl steffimycin A) aranciamycin 4 (identical to SM 173 A⁶) isolated in 1970 from cultures of *Streptomyces echinatus* and SM 173 B 5⁶.

The complete structure of aranciamycin has been recently secured by X-Ray analysis⁷ and it may be anticipated on the basis of anthracycline biosynthesis that steffimycin A 1 is in fact 2-methoxy aranciamycin. The recent publication by Krohn⁸ on the synthesis of 8-demethoxy aranciamycin leads us to describe here our own progress toward steffimycins.

Cycloaddition of the readily available ketene acetal 6⁹ with 3-chloro 5-hydroxy 7-methoxy 1,4-naphthoquinone 7, itself obtained by Diels-Alder condensation of Danishefsky diene (1-methoxy 3-trimethylsilyloxy 1,3-butadiene)¹⁰ with 2,6-dichlorobenzoquinone¹¹, affords after acidic hydrolysis olefin 8¹², m.p. 229-230°C, an orange powder (60%), as the only detectable regioisomer.








Epoxydation with metachloroperbenzoic acid (3 eq., CH₂Cl₂, 20°C) gives oxirane (\pm) 9 m.p. 233-234°C (70%)¹² together with some fully aromatized material.

Treatment of 9 with trifluoroacetic acid in CH₂Cl₂ at room temperature (16 hrs.) affords a mixture of cis 10a and trans 10b diols after cleavage of the intermediate trifluoroacetates with mild base (NaHCO₃) and, without separation, oxidation with Jones reagent (2 eq.) in acetone overnight gives (\pm) 11, m.p. 245-250°C as yellow powder (52% from 9)¹². This material which may be considered as 8-demethoxy 7-deoxy steffimycinone shows similar U.V. spectrum, in ethanol, to 7-deoxy steffimycinone (λ_{max} . 240 nm (log ϵ = 4.46), 285 nm (4.43) and 440 nm (4.23)^{2,13}.

As already observed by Krohn⁸ introduction of the C₇ hydroxyl group is easily carried out in this series by base treatment (Triton B, Pyridine, water) to give cis diol (\pm) 12, m.p. 223-225°C (61%)¹² together with variable amounts (\sim 0-6 %) of trans diol.

The formation of 12 is believed to arise through initial base catalyzed enolisation followed by addition of OH⁻ at C₇ and subsequent reoxidation to the quinone state. Standard benzylic bromination (Br₂, CCl₄, light in presence of epoxycyclohexane as HBr scavenger) affords after base treatment (Ca(OH)₂, THF, H₂O) a similar yield of (\pm) 12.

The relative stereochemistry at C₇ and C₉ in 12 has been confirmed by ¹H NMR¹² and quantitative conversion to the corresponding acetone (2-methoxy propene, cat. PTSA, room temperature).



ANTIBACTERIAL ACTIVITY

Compound 12 has been tested against gram-positive bacteria. Preliminary results indicate activity against *Bacillus subtilis* and *Bacillus pumilus* at 100 µg/ml. No activity was observed at this high concentration level against *Staphylococcus aureus*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Sarcina lutea*.

The presence of a C₈ methoxy group may be important for antibacterial activity since 7-deoxy steffimycinone¹³, aranciamycinone¹⁴ and SM 173 B inhibit gram-positive bacteria at much lower concentration.

Further efforts to prepare steffimycinone are in progress and extension of this synthetic methodology to analogs may bring more information about structural parameters necessary for antibacterial and/or antitumor activity.

Acknowledgments - We thank the CNRS and Laboratoires HOECHST (Paris) for financial support. Antibacterial screening was done at Institut Pasteur de Lyon (Laboratoire de Mycologie et microbiologie industrielle, Pr. R. GUINET).

References

- 1 - M.E. Bergy and F. Reusser, *Experientia*, 23, 254 (1967).
- 2 - R.C. Kelly, I. Schletter, J.M. Koert, F.A. Mc Kellar and P.F. Wiley, *J. Org. Chem.*, 42, 3591 (1977).

- 3 - Commonly used numbering of anthracyclines introduced by Brockmann.
- 4 - T.F. Brodasky and F. Reusser, *J. Antibiot.*, 27, 809 (1974).
- 5 - W. Keller-Schierlein, J. Sauerbier, U. Vogler and H. Zähler, *Helv. Chem. Acta*, 53, 779 (1970).
- 6a - A. Fujiwara, M. Tazoe, T. Hoshino, Y. Sekine and M. Fujiwara, *Koen Yoshishu-Tennen Yuki Kagobutsu Toronkai*, 22nd, 448 (1979).
- b - M. Fujiwara et al., *Chem. Abst.*, 89, 195 401 z (1978). *Japan Kokai* 78-99 000, Aug. 29 (1978) *Ger. Offen.* 2 804 495, Aug. 10 (1978).
- 7 - G.M. Sheldrick and A. Zeeck, unpublished result, see ref. 8.
- 8 - K. Krohn and E. Broser, *Liebigs, Ann. Chem.*, 1907, (1982).
- 9 - J.P. Gesson, J.C. Jacquesy and B. Renoux, see accompanying communication.
- 10 - S. Danishefsky and T. Kitahara, *J. Amer. Chem. Soc.*, 96, 7807 (1974).
- 11 - J. Savard and P. Brassard, *Tetrahedron Letters*, 4911, (1979).
- 12 - All new compounds exhibit analytical data and/or high resolution M.S. in agreement with the proposed structures. Melting points were taken on a Büchi 510 apparatus and are uncorrected. M.S. : Relative percentage of each fragments are given in parentheses.
- 8 NMR (CDCl₃) : δ 2.00 (s, 3H), 2.43 (t, J=7Hz, 2H), 2.86 (t, J=7Hz, 2H), 3.91 (s, 3H), 6.23 (s, 1H), 6.61 (s, 1H), 7.16 (s, large, 1H), 7.40 (s, large, 1H), 12.27 (s, 1H) and 12.33 (s, 1H), I.R (KBr) : 3275, 3030, 1680, 1640, 1620, 1600 cm⁻¹. M.S : m/z 336 (57), 334 (91), 274 (68), 238 (100), 175 (57) and 133 (82).
- 9 NMR (CDCl₃) : δ 1.55 (s, 3H), 3.66 (s, 1H), 3.90 (s, 3H), 6.64 (d, J=2Hz, 1H), 7.33 (d, J=2Hz, 1H), 7.79 (s, 1H), 12.20 (s, 1H) and 12.43 (s, 1H). I.R (KBr) : 3300, 3280, 1680, 1620, 1605 cm⁻¹. M.S : m/z 352 (47), 337 (23), 334 (26), 324 (100), 309 (23), 284 (10), 69 (38) and 51 (61).
- 11 NMR (CDCl₃) : δ 1.42 (s, 3H), 3.96 (s, 3H), 6.74 (s, large, 1H), 7.43 (s, large, 1H), 8.41 (s, 1H), 12.20 (s, 1H), 12.71 (s, 1H). I.R (KBr) : 3260, 3000, 1700, 1680, 1640, 1620 cm⁻¹. M.S : m/z 368 (58), 340 (52), 325 (100), 310 (17), 297 (52) and 282 (20).
- 12 NMR (CDCl₃) : δ 1.41 (s, 3H), 3.97 (s, 3H), 5.40 (t, J=6Hz, 1H), 6.76 (s, 1H), 7.43 (s, 1H), 8.44 (s, 1H), 12.08 (s, 1H), 13.14 (s, 1H). I.R (KBr) : 3360, 3020, 1710, 1680, 1620 cm⁻¹. U.V (EtOH) : 283 nm (log ϵ = 4.21), 240 nm (log ϵ = 4.38), 455 nm (log ϵ = 3.95). M.S. : m/z 384 (17), 368 (48), 366 (42), 350 (90), 338 (64), 324 (100), 297 (44), 277 (37) and 270 (33).
- 13 - R.C. Kelly, U.S. Pat. 3 976 667, Aug. 24 (1976).
- 14 - Interestingly aranciamycinone appears to be twice as potent against *Bacillus subtilis* (1-2 μ g/ml) as the parent aranciamycin (see ref. 5).

(Received in France 5 April 1983)